Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 14.59% and Operating profit at 5.07% over the last 5 years
2
The company has declared Positive results for the last 3 consecutive quarters
3
With ROE of 9.77%, it has a very attractive valuation with a 2.20 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,366 Million (Mid Cap)
23.00
NA
0.85%
0.13
9.77%
2.20
Revenue and Profits:
Net Sales:
301 Million
(Quarterly Results - Jun 2025)
Net Profit:
65 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.92%
0%
-2.92%
6 Months
-7.62%
0%
-7.62%
1 Year
-12.1%
0%
-12.1%
2 Years
30.37%
0%
30.37%
3 Years
-10.0%
0%
-10.0%
4 Years
2.35%
0%
2.35%
5 Years
0.43%
0%
0.43%
Zhejiang Garden Biopharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Zhejiang Garden Biopharmaceutical Adjusts Valuation Amidst Quality Score Reassessment
Zhejiang Garden Biopharmaceutical Co., Ltd. has recently experienced a change in its overall evaluation, influenced by adjustments in valuation and quality metrics. The company shows a fair valuation with manageable debt levels, while its operational performance has led to a reassessment of its quality score.
Read More Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.59%
EBIT Growth (5y)
5.07%
EBIT to Interest (avg)
19.11
Debt to EBITDA (avg)
0.40
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
0.24
Tax Ratio
14.10%
Dividend Payout Ratio
20.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.03%
ROE (avg)
12.07%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.20
EV to EBIT
22.26
EV to EBITDA
15.07
EV to Capital Employed
2.06
EV to Sales
6.24
PEG Ratio
0.45
Dividend Yield
0.85%
ROCE (Latest)
9.25%
ROE (Latest)
9.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
300.90
261.60
15.02%
Operating Profit (PBDIT) excl Other Income
116.40
93.30
24.76%
Interest
7.30
9.10
-19.78%
Exceptional Items
1.00
0.00
Consolidate Net Profit
65.00
50.60
28.46%
Operating Profit Margin (Excl OI)
241.90%
212.20%
2.97%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 15.02% vs -21.37% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 28.46% vs -22.51% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,220.20
1,075.60
13.44%
Operating Profit (PBDIT) excl Other Income
471.60
302.80
55.75%
Interest
36.00
38.70
-6.98%
Exceptional Items
0.30
0.80
-62.50%
Consolidate Net Profit
309.20
192.30
60.79%
Operating Profit Margin (Excl OI)
258.80%
157.50%
10.13%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 13.44% vs -23.24% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 60.79% vs -49.88% in Dec 2023
About Zhejiang Garden Biopharmaceutical Co., Ltd. 
Zhejiang Garden Biopharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






